After three years of hard work by multiple diverse stakeholders and with much anticipation, the RACE for Children Act became effective August 18 th, 2020. This landmark legislation aims to dramatically shift the global landscape of clinical research in pediatric oncology and intends to bring new molecularly targeted cancer therapeutics to children, who have not been as greatly impacted by precision medicine over the past few decades compared to adults. Whether the RACE for Children Act leads to the development of more drugs for children with cancer in the USA and globally remains to be seen. What can we learn about the global impact of the RACE for Children Act in the first few months since its implementation? Please join us in hearing from them on what the early global impact of the RACE for Children Act looks like, and what is needed to ensure its success, including the critical function of pediatric champions. PRA Health Sciences delivers innovative drug development solutions that improve patients’ lives. Over the years, we have contributed to the development of numerous drugs now available to countless patients.